Drugs & Targets FDA approves Ponlimsi to increase bone mass, including for breast and prostate cancer patients April 03, 2026Vol.52 No.13
Drugs & Targets FDA grants priority review to Elevar Therapeutics’s lirafugratinib as second-line cholangiocarcinoma treatment April 03, 2026Vol.52 No.13
Drugs & Targets FDA and EC approve Opdivo IO combinations in classical Hodgkin Lymphoma March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves relacorilant + nab-paclitaxel for platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer March 27, 2026Vol.52 No.12
Drugs & Targets FDA approves label update to accelerate thaw time for Adstiladrin gene therapy for NMIBC March 27, 2026Vol.52 No.12
Drugs & Targets PanTracer LBx liquid biopsy profiling test receives Medicare coverage March 20, 2026Vol.52 No.11
Drugs & Targets Sartorius launches platform to boost efficiency in cell therapy production March 20, 2026Vol.52 No.11
Drugs & Targets START, Trialing collaborate to expand access to oncology clinical trials across Europe March 20, 2026Vol.52 No.11
Drugs & Targets FDA approves Tecvayli + Darzalez Faspro for r/r MM as second line treatment March 13, 2026Vol.52 No.10
